α-Synuclein-lysosome axis central to Parkinson's pathogenesis, systematic review findsParkinson's protein and lysosome link may guide new treatments

This systematic review synthesizes current molecular evidence on the α-synuclein-lysosome axis in Parkinson's disease (PD). The review focuses on the interplay between α-synuclein protein aggregation and lysosomal dysfunction, highlighting this axis as a central mechanism in PD pathogenesis. The authors describe how impaired autophagy and lysosomal function contribute to α-synuclein accumulation and neurodegeneration.

Key findings emphasize that the α-synuclein-lysosome axis is a critical pathway in PD, with potential for therapeutic targeting. The review discusses emerging strategies aimed at modulating this axis, such as enhancing lysosomal function or reducing α-synuclein aggregation. However, the review does not provide clinical trial data or specific drug efficacy results; it is a synthesis of preclinical and mechanistic studies.

Limitations are not explicitly reported in the source, but the review's scope is confined to molecular mechanisms and does not include clinical outcomes. The authors aim to provide a theoretical foundation for novel therapeutic interventions, but no direct practice recommendations can be drawn from this review alone. Clinicians should interpret these findings as supporting the biological rationale for future therapies, not as evidence for current clinical use.